ALEX² is the next generation in vitro test for type I allergies. With an allergen panel of close to 300 allergen extracts and molecular allergens complemented by total IgE, we aim at above 99 % coverage of all routine diagnostic needs.
Our patent-pending technology was designed for testing hundreds of allergens in parallel without accepting a compromise on the performance of any single parameter.
The ALEX² assay protocol integrates a powerful Cross-reactive Carbohydrate Determinants (CCDs) inhibitor during serum incubation, which will clear up your specific IgE results. This reduces the interpretative burden for physicians of CCD positive patients and increases the specificity of our test results.
The quantification is based on a colorimetric image acquisition, using CMOS sensors and instrumentation.